The incubator anchored at the company's global headquarters in Raleighla launches alongside an inaugural partnership with Cape Fear BioCapital, a Durham-based seed-stage venture capital firm
As per the company’s Restated H1 2025 Financials, its continuing business delivered CORE EBITDA of CHF 922 million, representing a margin of 30.4%
Under the agreement, Apogee shareholders will receive $135.11 per share in cash, and the transaction has been unanimously approved by both companies’ boards
Bolstering neuroscience push with late-stage Tourette therapy
The FDA has granted Priority Review, setting a target decision date of 9 October 2026, potentially accelerating access to a new treatment option for a subset of patients with high-risk colon cancer characterized
Country’s deep scientific talent pool and its growing role as a clinical trial destination makes it central to how Parexel serves sponsors
Partnership strengthens healthcare technology distribution capabilities, enabling wider reach of Make-in-India medical devices through government and institutional healthcare networks
Through the transaction, Aurobindo USA will expand its product portfolio in this segment while gaining a U.S.-based manufacturing facility
Company becomes sole first applicant for 45 mg strength, positioning itself for potential 180-day generic exclusivity in the US market
Over 28 crore people screened, TB incidence falls sharply as Centre urges states to intensify efforts ahead of July campaign deadline
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
